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adova, Ancona, Reggio Emilia, Pisa, L’Aquila, Palermo, Legnano, Roma, Firenze, Torino, and
eggio Calabria, Italy
OBJECTIVES We prospectively investigated the prevalence of curable forms of primary aldosteronism (PA)
in newly diagnosed hypertensive patients.
BACKGROUND The prevalence of curable forms of PA is currently unknown, although retrospective data
suggest that it is not as low as commonly perceived.
METHODS Consecutive hypertensive patients referred to 14 hypertension centers underwent a diagnostic
protocol composed of measurement of Na and K in serum and 24-h urine, sitting plasma
renin activity, and aldosterone at baseline and after 50 mg captopril. The patients with an
aldosterone/renin ratio 40 at baseline, and/or 30 after captopril, and/or a probability of
PA (by a logistic discriminant function) 50% underwent imaging tests and adrenal vein
sampling (AVS) or adrenocortical scintigraphy to identify the underlying adrenal pathology.
An aldosterone-producing adenoma (APA) was diagnosed in patients who in addition to
excess autonomous aldosterone secretion showed: 1) lateralized aldosterone secretion at AVS
or adrenocortical scintigraphy, 2) adenoma at surgery and pathology, and 3) a blood pressure
decrease after adrenalectomy. Evidence of excess autonomous aldosterone secretion without
such criteria led to a diagnosis of idiopathic hyperaldosteronism (IHA).
RESULTS A total of 1,180 patients (age 46  12 years) were enrolled; a conclusive diagnosis was
attained in 1,125 (95.3%). Of these, 54 (4.8%) had an APA and 72 (6.4%) had an IHA. There
were more APA (62.5%) and fewer IHA cases (37.5%) at centers where AVS was available
(p  0.002); the opposite occurred where AVS was unavailable.
CONCLUSIONS In newly diagnosed hypertensive patients referred to hypertension centers, the prevalence of
APA is high (4.8%). The availability of AVS is essential for an accurate identification of the
adrenocortical pathologies underlying PA. (J Am Coll Cardiol 2006;48:2293–300) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.059by the American College of Cardiology Foundation
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brimary aldosteronism (PA) is a common cause of arterial
ypertension (HT); however, more than 50 years after its
iscovery (1) its prevalence in newly diagnosed hypertensive
atients remains uncertain. A survey of 18 recent studies
howed a wide range (from 1.4% to 32%, median 8.8%) of
stimates of prevalence (2). This is because most studies
ere performed retrospectively in a selected cohort of
atients and used heterogeneous criteria for selecting the
atients and diagnosing PA (3–15). Importantly, it should
lso be acknowledged that PA can only be conclusively
iagnosed in the patients who are cured or improved by
emoval of an aldosterone-producing adenoma (APA) or
nilateral adrenal hyperplasia (16). The other major PA
ubtype, idiopathic hyperaldosteronism (IHA), should not
For a list of author affiliations, please see the Appendix. Supported by grants from
ORICA (The Foundation for Advanced Research in Hypertension and Cardiovas-
ular Diseases) to Dr. Rossi and from the Societá Italiana dell’Ipertensione Arteriosa.e
Manuscript received May 10, 2006; revised manuscript received July 13, 2006,
ccepted July 23, 2006.e treated surgically and therefore cannot stand on this
etrospective criterion. Furthermore, differentiation of IHA
rom low-renin primary (essential) HT is arbitrary (7,17).
hus, establishing the prevalence of PA is a challenging
ask, which requires: 1) the prospective investigation of
ewly diagnosed consecutive unselected hypertensive pa-
ients, 2) the use of predefined state-of-the-art diagnostic
riteria, and 3) an unequivocal diagnosis that is feasible only
etrospectively in APA treated with adrenalectomy. A study
f the unselected hypertensive patients, seen by general
ractitioners, is hard to perform and to justify for cost-
ffectiveness reasons; furthermore, it can be hampered by
he difficulty of achieving a conclusive diagnosis of PA and
f its underlying cause, which requires the expertise and
acilities that are usually available only at specialized centers.
he only attempt in this direction best testifies this difficulty
ecause it furnished data only on the prevalence of an
levated aldosterone/renin ratio (ARR) and not of PA (18).
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Diagnosis of Hyperaldosteronism December 5, 2006:2293–300A large-scale multicenter study carried out prospectively
t referral centers could minimize the chances of selection
iases and furnish firm evidence on the accuracy of diag-
ostic tests for PA (19). Hence, at the end of 2001 a
orking Group of the Italian Society of Arterial Hyper-
ension started nationwide a prospective survey aimed at
etermining the prevalence of APA in newly diagnosed
ypertensive patients referred to specialized centers for HT
n Italy. This article reports on the main results of this
nvestigation that was named the PAPY (PA Prevalence in
ypertensives) study, whereas data on early renal involve-
ent have been reported elsewhere (20).
igure 1. This flowchart shows the protocol for the recruitment and invest
Abbreviations and Acronyms
APA  aldosterone-producing adenoma
ARR  aldosterone/renin ratio
AVS  adrenal vein sampling
CT  computed tomography
HT  hypertension
IHA  idiopathic hyperaldosteronism
LDF  logistic discriminant analysis
MR  magnetic resonance
PA  primary aldosteronism
PRA  plasma renin activityAmerican Heart Association; APA aldosterone-producing adenoma; ARR
omography; IHA  idiopathic hyperaldosteronism; LDF  logistic discriminaETHODS
verview. The study design followed the recommenda-
ions of the STARD (Statement for Reporting Studies of
iagnostic Accuracy) (21). The protocol (Fig. 1) was
pproved by the ethical committee of the University of
adua, and an informed written consent was obtained from
ach participant. To minimize the chance of any selection
ias, it was decided a priori to enroll consecutive patients
ith a new (within the previous 6 months) diagnosis of HT
ho had been referred by their family doctor to specialized
enters for the diagnosis and treatment of HT nationwide in
taly. A prior diagnosis of any secondary forms of HT and
he patient’s refusal to participate in the study were exclu-
ion criteria. To ensure homogeneity across centers, it was
ecided a priori to exclude from the analysis centers that
ventually would have recruited fewer than 20 patients.
creening test. Patients were enrolled after the diagnosis
f HT was confirmed by established criteria based on office
lood pressure measurement by mercury sphygmomanom-
ter (22). The patients had to be prepared for the screening
est as follows: treatment with spironolactone, canrenone, or
otassium canrenoate was withdrawn for at least 6 weeks
Fig. 1). Other agents, including diuretics, beta-blockers,
ngiotensin-converting enzyme inhibitors, and angiotensin
n of the PAPY (PA Prevalence in Hypertensives) study population. AHAigatio
aldosterone/renin ratio; AVS adrenal vein sampling; CT computed
nt analysis; MR  magnetic resonance.
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December 5, 2006:2293–300 Diagnosis of HyperaldosteronismI type 1 (AT-1) receptor antagonists, were withdrawn for
t least 2 weeks. A long-acting calcium channel blocker
nd/or doxazosin were allowed as treatment whenever
ecessary for minimizing the risks of uncontrolled HT. On
he day of the test, Na and K excretion was measured by
4-h urine collection. The completeness of the urine col-
ection was verified with measurement of urinary creatinine
xcretion.
After an overnight fast and 1 h quiet rest in the sitting
osition, between 7 AM and 9 AM the Na and K, plasma
enin activity (PRA), aldosterone, and cortisol were mea-
ured at baseline and again 60 min after captopril adminis-
ration (50 mg orally). The blood pressure levels were
easured at baseline and after captopril as previously
escribed.
The aldosterone (in ng/dl)/PRA (in ng/ml/h) ratio, at
aseline and after captopril, and a score estimating the
robability of PA based on a validated multivariate logistic
iscriminant analysis (LDF) score (7) were calculated.
dditional tests. A saline infusion test (2 l saline over 4 h
ith the patients kept in the supine position) (23), with
easurement of PRA, aldosterone, cortisol, and serum K
t baseline and again after the infusion, was performed in all
atients with: 1) an ARR 40 baseline, and/or 2) an ARR
30 after captopril (24), and/or 3) an LDF score 0.50; as
ell as 1 in every 4 patients not meeting such criteria. The
eed for further testing was decided based on the ARR at
aseline and the captopril test results, regardless of the saline
est results. It was decided that this test should not affect the
urther diagnostic workup to avoid any bias in the evaluation
f the performance of the saline as a confirmatory test for
A.
A high-resolution computed tomography (CT) scan with
-mm slices and systematic use of a contrast medium,
nd/or magnetic resonance (MR) imaging, was required in
ll patients with an ARR 40 baseline and an ARR 30
fter captopril, or an LDF score 0.50. The adrenal
odular enlargements, identified with CT and/or MR
maging, were classified by diameter into 3 classes: 10
m, 11 to 20 mm, and 20 mm. The kappa value
etween radiologists in classifying these lesions was 0.954
p  0.001). At the centers where adrenal vein sampling
AVS) (25) was available, it was performed in all of those
elected for CT and/or MR as previously described.
examethasone-suppressed adrenocortical scintigraphy
26) was used to show a lateralized aldosterone excess
roduction whenever AVS was unavailable. The AVS was
erformed without ACTH stimulation because the latter
as shown not to improve the diagnostic accuracy (27).
nly bilaterally selective AVS were judged to provide an
ccurate diagnosis. The criteria for considering AVS selec-
ive and for lateralization of aldosterone secretion were
reviously established as described in detail (25).
iochemical measurements. The utmost care was taken in
rawing blood by avoiding a tourniquet, fist clenching, and
ny condition that might artificially increase serum K (28). hhe Na and K levels were measured in serum and urine
y the standard method; hypokalemia was defined as serum
 3.5 mEq/l. The glomerular filtration rate was mea-
ured using the abbreviated equation (29). Plasma renin
ctivity was measured by radioimmunoassay with commer-
ial kits (Ren CTK, Sorin Biomedica Saluggia, Italy, in 10
enters; or Angiotensin I RIA CT, Radim, Pomezia, Italy,
n the remainder). For both kits, the intra-assay and
nterassay coefficient of variation was within 8% and 10%.
ormal range sitting, at rest, and on a normal Na diet was
.65 to 2.64 ng/ml/h. The assay for aldosterone was
erformed with a commercial kit (Aldosterone Mirya,
echogenetics, Cassina de Pecchi, Italy). Normal range was
0 to 150 pg/ml supine and 30 to 320 pg/ml upright on a
ormal Na diet; both intra-assay and interassay coefficients
f variation for this assay were5.6%; the cross-reactivity of
he antibody for aldosterone for the other adrenal steroids
as0.001%. Cortisol was measured with a commercial kit
Cortisol bridge, Adaltis, Casalecchio di Reno, Italy); the
ntra-assay and interassay coefficients of variation for this
ssay were below 6% and 10 %, respectively. The cross-
eactivity of the antibody for steroids was negligible. A
urvey of hormone values shows no differences across
enters; sample centralization in a single laboratory (Padua)
or a quality control project is ongoing.
iagnostic criteria. The Working Group reached the
onsensus that a positive result of the ARR baseline had to
e corroborated by the result of the captopril test. Hence,
he diagnosis of PA required evidence of autonomous excess
ldosterone production, which was defined as an ARR 40
t baseline plus an ARR 30 after captopril, or a logistic
iscriminant function 0.50 (7,24). For the calculation of
he ARR the PRA values 0.2 ng/ml/h were arbitrarily set
o 0.2. On completion of the diagnostic workup described in
igure 1, an Adjudication Committee (G.P.R., F.M.) was
esponsible for determining whether patients had PA or
ot. Moreover, the diagnosis of APA required the following
trict predefined criteria: 1) lateralization of aldosterone
ecretion at AVS, or evidence of lateralized uptake of
31I-norcholesterol at dexamethasone-suppressed adreno-
ortical scintigraphy, 2) surgery, 3) pathology, and more
mportantly, 4) outcome of adrenalectomy as assessed at
ollow-up. To this end, we required demonstration of
ormokalemia and cure or improvement of HT at least 120
ays after adrenalectomy according to the American Heart
ssociation criteria for evaluation of outcome after correc-
ion of renal ischemia (30). Cure was defined as a systolic
lood pressure 140 mm Hg and diastolic blood pressure
90 mm Hg without medications, and improvement as a
ystolic and diastolic blood pressure 140/90 mm Hg,
espectively, on the same or a reduced number of medica-
ions and/or a reduced number of defined daily doses (31).
y exclusion, patients with a biochemical diagnosis of PA
ithout evidence for a lateralized aldosterone excess were
eld to have IHA.
S
f
t
n
l
v
v
c
c
o
p
m
p
1
c
t
e
a
o
w
t
f
M
t
R
C
b
e
f
h
t
w
i
P
a
h
u
d
e
e
s
e
t
t
L
a
e
C
5
t
1
n
P
1
w
c
r
t
c
p
e
a
S
t
e
(
a
2296 Rossi et al. JACC Vol. 48, No. 11, 2006
Diagnosis of Hyperaldosteronism December 5, 2006:2293–300tatistical analysis. Quantitative variables were first tested
or normal distribution, and transformations were under-
aken for variables that showed a skewed distribution until a
ormal distribution was attained. One-way ANOVA fol-
owed by a Bonferroni test was used to compare quantitative
ariables between groups. The distribution of categorical
ariables was investigated by chi-square analysis. Signifi-
ance was set at p  0.05.
The sensitivity, specificity, and accuracy of each test were
alculated (32). The diagnostic odds ratio, that is the odds
f positivity among diseased patients divided by the odds of
ositivity among nondiseased patients, was also used as
easure of the diagnostic accuracy (19). When a test
rovides no diagnostic evidence, the diagnostic odds ratio is
.0. The area under the receiver operator characteristics
urve was also used to measure and compare the accuracy of
he tests (32), for example, serum K, ratio of urinary K
xcretion to serum K, ARR at baseline and after captopril,
nd the logistic discriminant function score, for prediction
f the conclusive diagnosis of PA or no PA. This strategy
as also used to determine the cutoff values that provided
he best combination of sensitivity and false-positive rate
or each test. The MedCalc software (version 8.1.1.0,
edCalc Software, Mariakerke, Belgium) was used for
hese purposes.
ESULTS
linical and demographic features. On locking the data-
ase on September 30, 2004, 4 of the 18 centers had
nrolled fewer than 20 patients, and therefore were excluded
rom the analysis. An additional 17 patients who did not
ave complete hormone data or showed some violation of
he protocol were excluded. Thus, overall 1,180 patients
ere available for the analysis; their baseline data are shown
n Table 1. The comparison of patients with and without
Table 1. Demographic Characteristic of the Pa
Who Had a Conclusive Diagnosis
Variable (n
Gender (male/female), % (range) 74/5
Age (yrs) 49.7
Body mass index 27.4
Systolic BP (mm Hg) 155
Diastolic BP (mm Hg) 98
HR (beats/min) 72
Serum K (mmol/l) 3.6 (
Serum Na (mmol/l) 141 (
Urinary K (mmol/24 h) 59 (
Urinary Na (mmol/24 h) 137
Glomerular filtration rate (ml/min) 84
sPRA (ng·ml1·h) 0.62 (
s-Aldosterone (pg/ml) 297 (1
s-Cortisol (ng/ml) 135
Data are mean  SEM; except for serum and urinary K, seru
median (range) are shown. Normal values for s-aldosterone
ng/ml.
BP  blood pressure; HR  heart rate; K  potassium le
s-Aldosterone  sitting plasma aldosterone; s-PRA  sitting plasA showed not only the expected differences of PRA,
ldosterone, and serum K, but also an older age and a
igher blood pressure in the PA group.
At the time of the screening test, 40% of the patients were
ntreated, 42% were on a calcium channel blocker or
oxazosin, and 18% were on both agents. No patients
xperienced any problem while untreated, and no untoward
ffect occurred with captopril administration. There were no
ignificant differences of PRA, aldosterone, and cortisol in
ither the entire group or PA or the PH patients across
reatment groups, thus ruling out any systematic effect of
hese treatments on the results of the screening test (33,34).
ikewise, there were no differences in PRA, aldosterone,
nd cortisol across centers, thus making unlikely a center
ffect on hormonal data.
onclusive diagnosis. At the time of the database locking,
3 patients had not completed the entire diagnostic workup;
herefore, a conclusive diagnosis was attained in 95.3% (n
,125) of the 1,180 patients. On completion of the diag-
ostic workup (Fig. 1), 126 patients were diagnosed with
A. Therefore, overall the prevalence of the disease was
1.2%, without gender differences (11.7% in men, 10.6%. in
omen). By the aforementioned criteria, an APA was the
ause of PA in 54 patients (42.8%), and IHA in the
emaining 72 (57.2%). Heterogeneity in the proportion of
he underlying adrenal pathologies (p  0.001) across
enters was observed. When the 2 centers with the highest
revalence that contributed most to this heterogeneity were
xcluded, the overall prevalence of PA and APA was 7.4%
nd 3.5%, respectively.
creening test. Overall 20.4% of the patients tested posi-
ive by at least 1 of the indexes derived from the baseline
valuation and the captopril test by the prespecified criteria
7,24). Table 2 shows the sensitivity, specificity, accuracy,
nd diagnostic odds ratio (19) of each test at the prespecified
s (n  1,125) Enrolled in the PAPY Study
Non-PA
p Value6) (n  999)
41) 560/439 (56:44)
.2 45.9  12.0 0.03
5 26.9  4.6 NS
147  17 0.0001
95  10 0.0001
72  10 NS
.7) 4.0 (2.6–5.5) 0.0001
50) 141 (130–152) NS
2) 61 (12–367) NS
12) 160 (15–826) 0.02
86  20 NS
0.96) 1.66 (0.2–43.5) 0.0001
,260) 116 (10–248) 0.0001
9) 143 (11–520) NS
urinary Na, s-aldosterone, s-PRA, and s-cortisol, for which
150 pg/ml; s-PRA: 0.51–2.64 ng/ml/h; s-cortisol: 50–250
tient
PA
 12
2 (59:
 12
 4.
 19
 11
 9
2.2–4
134–1
13–16
(16–4
 17
0.02–
70–2
(5–30
m and
: 20–vel; Na  sodium level; PA  primary aldosteronism;
ma renin activity.
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December 5, 2006:2293–300 Diagnosis of Hyperaldosteronismutoffs. Thus, the screening tests allowed selection of
ubgroups of hypertensive patients with a higher prevalence
f PA. Of the indexes based on the captopril test, the ARR
fter captopril had a lower sensitivity and a higher specificity
han the ARR at baseline, whereas the opposite occurred for
he LDF score. The latter showed the highest sensitivity,
nd therefore the highest diagnostic odds ratio.
dditional tests. The comparison of the diagnostic perfor-
ances of the saline suppression test and the captopril test
or confirming the diagnosis of PA will be reported
lsewhere.
Based on the maximum tumor diameter at CT and MR,
7% of the APA was 10 mm diameter; 28% between 10
nd 20 mm; and 55% 20 mm.
revalence of hypokalemia by conclusive diagnosis. S-
ontaneous hypokalemia was found in 9.6% of the patients;
owever, it was observed in about one-half of the patients
ith APA and only 17% of those with IHA (Fig. 2).
everity of arterial HT by conclusive diagnosis. Figure 3
hows the prevalence of APA and IHA in the patients
lassified by blood pressure values at the screening test.
igh-normal blood pressure (because of ongoing treatment)
as seen in about 12% of the patients; despite ongoing
reatment 43% of the patients had grade 1, 31% grade 2, and
3.7% grade 3 HT (22). Increasing severity of HT was
Table 2. Sensitivity, Specificity, Overall Accura
the Prespecified Cutoffs
Variable Sensitivity (%)
ARR 40 baseline 68
ARR 30 captopril 59
LDF score 50 91
The diagnostic odds ratio (DOR), calculated as the odds of p
among nondiseased persons, provides an overall measure of
evidence, the DOR is 1.0.
ARR  aldosterone (ng/dl)/renin (ng/ml/h) ratio; LDF
igure 2. This bar graph shows that a substantial proportion of the patients
ith APA and IHA did not have hypokalemia (red bars) at the time of
resentation. APA  aldosterone-producing adenoma; IHA  idiopathic
yperaldosteronism; PH  primary hypertension.
h
hssociated with an increased prevalence of both APA and
HA (chi-square  31.4, p  0.0001).
eceiver-operating characteristic curve analysis. By
eceiver-operating characteristic curve analysis, the accuracy
f the ratio of 24-h urinary K excretion to serum K did
ot differ from 0.5, whereas those for ARR at baseline and
fter captopril and the logistic discriminant function score
ere significantly higher (see online supplemental table).
he logistic discriminant function score showed the highest
ccuracy, followed by the ARR after captopril, and the ARR
t baseline, which all performed better (p  0.0001) than
erum K. The online supplemental table shows that the
utoff values that provided the best tradeoff of sensitivity and
pecificity for each test differed from those prespecified
ased on retrospective studies (14,35).
mpact of AVS on subtypes of PA. The AVS was avail-
ble at 5 of the 14 centers that qualified for the study and
as performed in 43 patients; however, it was bilaterally
elective in 40 (93%) of the patients. Hence, the hypothesis
hat the availability of AVS affects the prevalence of
drenocortical pathologies underlying PA could be tested by
plitting the centers into those with and those without AVS.
e found that at the centers with AVS significantly more
ases of APA and fewer cases of IHA were diagnosed
nd Diagnostic Odds Ratio of Each Test at
ecificity (%) Accuracy (%) DOR
87 92 14.1
91 94 14.6
80 87 42.5
ity among diseased persons divided by the odds of positivity
agnostic accuracy (19). When a test provides no diagnostic
stic discriminant analysis.
igure 3. This bar graph shows the proportion of patients without PA
white bars), with IHA (red bars), and with APA (black bars) in the
atients at the screening test. The proportion of patients with PA caused
y both APA and IHA increased significantly (from 7.2% to 19.5%) with
he increasing severity of hypertension. APA  aldosterone-producing
denoma; BP  blood pressure; HT  hypertension; IHA  idiopathiccy, a
Sp
ositiv
the diyperaldosteronism; PA  primary aldosteronism; PH  primary
ypertension.
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Diagnosis of Hyperaldosteronism December 5, 2006:2293–300Fig. 4). The opposite occurred at the centers where AVS
as unavailable.
ISCUSSION
ompelling evidence indicates that hyperaldosteronism is
ssociated with detrimental consequences on the cardiovas-
ular system (36), including early renal damage (20). Re-
oval of an APA or a unilateral autonomous hyperplasia
ormalizes aldosterone secretion, and warrants cure or
arked amelioration of HT, and the cardiovascular changes
n most patients (37). The systematic search for PA and
fforts toward identifying unilateral causes of aldosterone
ecretion could therefore be justified, particularly if the
revalence of PA were high as suggested (2–15,38), al-
hough the cost effectiveness of this strategy has been
hallenged (39).
This multicenter study prospectively investigated the
revalence of APA and PA with a predefined diagnostic
rotocol in newly diagnosed hypertensive patients re-
erred to specialized centers for HT nationwide. State-
f-the-art tests (40) and a consensus protocol for diag-
osing APA were exploited, thus allowing a conclusive
stablishment of the presence or absence of the disease.
ecause of these unique features, robust evidence on the
revalence of this potentially curable form of arterial HT
nd information that may affect future strategies for the
creening and diagnosing PA and its underlying causes
ould be obtained.
revalence of PA. Only APA can be unequivocally diag-
osed with strict criteria such as those described; at variance,
o such diagnostic gold standard exists for identifying IHA
7,17). Thus, although we found that the overall prevalence
f PA was 11.2%, which accords well with an earlier
rediction (3,5), we would like to underline that an APA
as found in 42% of the cases initially held to have PA.
hus, 4.4% of the 1,180 consecutive hypertensive patients
igure 4. This histogram shows the proportion of PA patients with
PA (black bars) and IHA (red bars) by availability of adrenal vein
ampling (AVS) in the participating centers. APA  aldosterone-
roducing adenoma; IHA  idiopathic hyperaldosteronism; PA 
rimary aldosteronism.riginally screened (and 4.6% of those with a conclusive Kiagnosis) had an APA that was surgically removed with a
ong-term cure. This figure might underestimate the pro-
ortion of APA for several reasons. First, because we used a
ather high ARR baseline for the initial screening, which
an provide a higher specificity but a lower sensitivity than
ower cutoffs, some PA patients might have been missed.
econd, we unexpectedly found a high rate of spontaneous
ypokalemia in the patients without PA. Because hypoka-
emia lowers aldosterone secretion, some of these patients
ight have had falsely normal aldosterone, which might
ave been revealed if they had been studied when nor-
okalemic. A few of them might also have apparent
ineralocorticoid excess, Liddle syndrome, familial type I
yperaldosteronism (glucocorticoid-remediable aldosteron-
sm), or another undefined cause of primary HT with
ypokalemia. Unfortunately, in this multicenter study we
ad no opportunity to reinvestigate these patients after
orrection of the hypokalemia and to dissect these mono-
enetic forms of HT. Finally, at centers where AVS was
navailable, IHA was diagnosed by exclusion of an APA. As
iscussed later, the tests used as an alternative to AVS (CT
r MR and dexamethasone-suppressed adrenocortical scin-
igraphy) are inaccurate for diagnosing a small APA, thus
uggesting that some APAs have been missed at these
enters.
eneralizability of the results. Our patients were re-
erred to a specialized HT center. We found a heteroge-
eity of PA prevalence across centers, which suggests
ccurrence of some referral bias despite all of the precau-
ions that were taken. The relevance of our results to the
racticing generalist evaluating patients with HT may
herefore be questioned. The following considerations,
owever, are necessary. First, patients were enrolled
onsecutively without applying any selection criteria
such as serum K, blood pressure levels, and/or resis-
ance to the antihypertensive treatment). Second, pa-
ients who had any clues to a secondary form of HT were
arefully excluded. Third, the anthropometric and blood
ressure data (Table 1) are similar to those of the general
talian population of hypertensive individuals. Fourth,
he prevalence of a high ARR in this study was even
ower than the 32.4% prevalence of a high ARR found in
general practitioners study in Italy, despite the use of a
igher (50) cutoff (18). Finally, even after the exclusion
f the centers with the highest prevalence of PA, the rate
f APA remained around 3.5%. Thus, while retaining
eneral validity, our data support the view that the
creening for PA in the newly diagnosed hypertensive
atients is justified and can open the door to a cure of
rterial HT in several cases.
creening tests. We calculated the ARR at baseline and 2
dditional indexes, the ARR after captopril and the logistic
iscriminant function score, that are viewed as confirmatory
ests (40). These indexes outperformed spontaneous hypo-
alemia and the ratio of 24-h urinary K excretion to serum
 when compared by receiver-operating characteristic
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ecause a substantial proportion of our patients without PA
ad hypokalemia and conversely, most patients with con-
rmed PA had normokalemia (Fig. 2). Thus, nowadays the
ormokalemic cases of PA seem to be the rule rather than
he exception, in accord with most studies (7,41), albeit not
ll of the retrospective studies (10). The widespread use of
ow-sodium and/or high-potassium diets along with the
ore diffuse prescription of potassium-sparing antihyper-
ensive drugs, such as angiotensin-converting enzyme in-
ibitors and AT-1 receptor antagonists, which were not
ermitted in this study, are likely explanations for the
urrent common occurrence of normokalemic cases of PA.
linically, this result implies that if hypokalemia were to be
sed as a screening test, the majority of the PAs would have
een missed (7,14,40,41).
ests for identifying the underlying adrenal pathol-
gy. The use of high-resolution CT and MR scans has
hown that the diameter of APA is generally smaller than
0 mm and often smaller than 10 mm (25). In this study
5% of the APAs discovered by CT or MR were smaller
han 20 mm, and 17% were smaller than 10 mm. This
nding accords well with the 12.4-mm mean diameter of a
ecent report (42). Because these small tumors can escape
etection with all imaging techniques, it is not surprising
hat they could be accurately identified with CT or MR only
n about one-half of the cases (42). Considering the high
revalence of arterial HT (22) and incidentally discovered
drenal masses (43), of which only 1.6% are APAs (44), the
oncurrence by chance of primary HT and nonfunctioning
drenal tumors is, according to conditional probability
alculation (Bayes rule), about 3.6%.
We and others proposed that AVS is crucial to show
ateralization of aldosterone secretion from the affected
drenal gland in the commonly occurring small-sized
PA (25,42,45). Hence, the lack of performing AVS
ight affect the proportion of PA attributed to APA or
HA. This hypothesis, which has never been tested in a
arge multicenter study, was confirmed by comparing the
iagnoses made at the centers that could perform AVS
ith those made at the centers where this test was
navailable: the former centers diagnosed more APAs
han the latter centers, where more cases of PA had to be
ttributed to IHA. Therefore, an accurate diagnosis of
he adrenocortical pathology underlying PA requires
VS. This test is technically demanding and not univer-
ally available, but can be performed at a very low (0.5%
o 1%) risk of major complications in experienced hands
42,46).
onclusions. Almost 5% of the newly diagnosed hyper-
ensive patients who are referred to specialized centers for
T have a surgically curable APA. However, this figure
ight underestimate the true prevalence of the tumors
ecause of the lack of systematic use of AVS. An additional
.4% of case had IHA, thus resulting in an overall preva-
ence of PA of about 11.2%. Given the high prevalence ofrterial HT, screening for PA is warranted in newly diag-
osed hypertensive patients. The biochemical identification
f PA represents a compelling indication for the search of a
nilateral adrenal cause of aldosterone excess, which is
easible with AVS and is mandatory before undertaking
drenalectomy.
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